iCAD Croissance future

Future contrôle des critères 1/6

iCAD devrait augmenter ses bénéfices et ses revenus de 20.4% et de 18.6% par an respectivement, tandis que le BPA devrait croître de croître de 22.2% par an.

Informations clés

20.4%

Taux de croissance des bénéfices

22.2%

Taux de croissance du BPA

Healthcare Services croissance des bénéfices	28.1%
Taux de croissance des recettes	18.6%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	04 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% But Many Are Still Ignoring The Company

Aug 21

iCAD, Inc.'s (NASDAQ:ICAD) P/S Still Appears To Be Reasonable

Jun 27

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Feb 29

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:ICAD - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	29	-3	N/A	N/A	2
12/31/2025	24	-6	N/A	N/A	2
12/31/2024	19	-7	N/A	N/A	2
6/30/2024	19	-5	-5	-4	N/A
3/31/2024	18	-5	-6	-5	N/A
12/31/2023	17	-7	-6	-5	N/A
9/30/2023	17	-9	-7	-7	N/A
6/30/2023	18	-11	-8	-8	N/A
3/31/2023	17	-9	-10	-10	N/A
12/31/2022	20	-10	-13	-13	N/A
9/30/2022	23	-12	-12	-11	N/A
6/30/2022	28	-11	-11	-11	N/A
3/31/2022	33	-13	-11	-10	N/A
12/31/2021	34	-11	-10	-9	N/A
9/30/2021	36	-9	-9	-9	N/A
6/30/2021	34	-8	-10	-9	N/A
3/31/2021	32	-7	-10	-9	N/A
12/31/2020	30	-18	-7	-7	N/A
9/30/2020	29	-19	-9	-8	N/A
6/30/2020	29	-21	-9	-8	N/A
3/31/2020	31	-22	-7	-7	N/A
12/31/2019	31	-14	-7	-7	N/A
9/30/2019	29	-14	-7	-6	N/A
6/30/2019	27	-12	-5	-5	N/A
3/31/2019	26	-9	-5	-5	N/A
12/31/2018	26	-9	-4	-4	N/A
9/30/2018	27	-10	-4	-4	N/A
6/30/2018	27	-15	-6	-6	N/A
3/31/2018	28	-17	N/A	-6	N/A
12/31/2017	28	-14	N/A	-7	N/A
9/30/2017	27	-13	N/A	-7	N/A
6/30/2017	26	-9	N/A	-6	N/A
3/31/2017	27	-8	N/A	-5	N/A
12/31/2016	26	-10	N/A	-5	N/A
9/30/2016	27	-9	N/A	-6	N/A
6/30/2016	31	-7	N/A	-5	N/A
3/31/2016	34	-33	N/A	-4	N/A
12/31/2015	42	-32	N/A	-2	N/A
9/30/2015	48	-30	N/A	3	N/A
6/30/2015	50	-29	N/A	6	N/A
3/31/2015	49	-3	N/A	5	N/A
12/31/2014	44	-1	N/A	3	N/A
9/30/2014	39	-5	N/A	2	N/A
6/30/2014	35	-6	N/A	-3	N/A
3/31/2014	33	-7	N/A	-2	N/A
12/31/2013	33	-8	N/A	-1	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ICAD devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: ICAD devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: ICAD devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ICAD ( 18.6% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ICAD ( 18.6% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ICAD devrait être élevé dans 3 ans

iCAD Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates fall by 18%, revenue upgraded

Forecast to breakeven in 2026

No longer forecast to breakeven

Consensus revenue estimates fall by 12%

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 16%

Recent updates

iCAD, Inc. to Report Q3, 2024 Results on Nov 13, 2024

iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% But Many Are Still Ignoring The Company

Consensus EPS estimates fall by 18%, revenue upgraded

New major risk - Revenue and earnings growth

iCAD, Inc. to Report Q2, 2024 Results on Aug 13, 2024

iCAD, Inc.'s (NASDAQ:ICAD) P/S Still Appears To Be Reasonable

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2026

iCAD, Inc. to Report Q1, 2024 Results on May 15, 2024

iCAD, Inc., Annual General Meeting, Jun 13, 2024

No longer forecast to breakeven

iCAD, Inc. Showcases New Profound Cloud, Enhanced Profound Detection Workstation Features at SBI Annual Symposium

iCAD, Inc. Announces Commercial Availability of ProFound Cloud

Consensus revenue estimates fall by 12%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

iCAD, Inc. to Report Q4, 2023 Results on Mar 12, 2024

iCAD, Inc. Appoints Michael John Doyle to its Board of Directors

Forecast to breakeven in 2026

iCAD, Inc. Expands Executive Sales Leadership Team as Business Grows

iCAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite

iCAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 16%

iCAD, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Profitability

Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).

We're Hopeful That iCAD (NASDAQ:ICAD) Will Use Its Cash Wisely

Consensus EPS estimates upgraded to US$0.37 loss, revenue downgraded

Health Canada Grants Device License for iCAD's Profound Risk 2.0, Revolutionizing Breast Cancer Risk Via A 1-2 Year Assessment

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

iCAD, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Price target increased by 10% to US$4.88

We Think iCAD (NASDAQ:ICAD) Needs To Drive Business Growth Carefully

Consensus EPS estimates fall by 22%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Executive Chair recently bought US$52k worth of stock

No longer forecast to breakeven

Price target decreased by 38% to US$5.08

Will iCAD (NASDAQ:ICAD) Spend Its Cash Wisely?

iCAD, Inc. Appoints Bill Keyes as Senior Vice President, US Commercial Sales, AI

iCAD, Inc. Appoints Dana Brown as Executive Chair of the Board of Directors

iCAD, Inc. Announces Nathaniel Dalton's Resignation from His Position as A Member of the Board

Consensus revenue estimates fall by 11%

Price target decreased to US$8.17

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Is iCAD (NASDAQ:ICAD) In A Good Position To Invest In Growth?

iCAD, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus revenue estimates fall by 15%

Forecast to breakeven in 2024

iCAD, Inc. to Report Q2, 2022 Results on Aug 10, 2022

iCAD, Inc.(NasdaqCM:ICAD) dropped from Russell 2000 Dynamic Index

Companies Like iCAD (NASDAQ:ICAD) Are In A Position To Invest In Growth

iCad, Inc. Announces CFO Changes

Icad, Inc. Announces Chief Financial Officer Changes

Icad, Inc. Announces That New Research Supporting Profound Ai for Digital Breast Tomosynthesis

iCAD, Inc. Announces Promising Clinical Research Supporting Profound Ai(R) Risk for Digital Breast Tomosynthesis

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

iCAD, Inc., Annual General Meeting, Jun 17, 2022

iCAD Announces Significant Commercial Momentum for ProFound AI Among Customers Equipped with the Provider of 3D Mammography Systems

No longer forecast to breakeven

iCAD, Inc. Announces Board Changes

iCAD, Inc. Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy for Brain, Rectal, Head and Neck Tumor Treatment

Consensus EPS estimates fall by 71%

Full year 2021 earnings: EPS exceeds analyst expectations